{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:54:16Z","timestamp":1785855256818,"version":"3.56.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacc.2026.06.012","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:31:36Z","timestamp":1785853896000},"page":"559-562","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacotherapy for Management of Type 2 Diabetes and CKM Syndrome"],"prefix":"10.1016","volume":"88","author":[{"given":"Ambarish","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kershaw V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.06.012_bib1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41569-019-0241-y","article-title":"Long-term follow-up of intensive glycaemic control in type 2 diabetes","volume":"16","author":"Patel","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2026.06.012_bib2","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"22S","key":"10.1016\/j.jacc.2026.06.012_bib3","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1016\/j.jacc.2026.03.056","article-title":"2026 AHA\/ACC\/ADA\/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome","volume":"87","author":"Ndumele","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.012_bib4","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.jacc.2025.05.007","volume":"86","author":"Jones","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.012_bib5","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Blumenthal","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.06.012_bib6","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/CIRCULATIONAHA.123.067530","article-title":"Optimal screening for predicting and preventing the risk of heart failure among adults with diabetes without atherosclerotic cardiovascular disease: a pooled cohort analysis","volume":"149","author":"Patel","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.06.012_bib7","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jcmg.2020.12.024","article-title":"Coronary artery calcium for the allocation of GLP-1RA for primary prevention of atherosclerotic cardiovascular disease","volume":"14","author":"Cainzos-Achirica","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.jacc.2026.06.012_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchf.2026.103153","article-title":"Screening and treatment using a risk-based approach with NT-proBNP guidance in diabetes mellitus: the STRONG-DM pilot study","author":"Subramanian","year":"2026","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jacc.2026.06.012_bib9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1001\/jamacardio.2025.0871","article-title":"Leveraging preexisting cardiovascular data to improve the detection and treatment of hypertension: the NOTIFY-LVH randomized clinical trial","volume":"10","author":"Berman","year":"2025","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.06.012_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11892-018-1035-z","article-title":"Should metformin remain first-line medical therapy for patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease? An alternative approach","volume":"18","author":"Harrington","year":"2018","journal-title":"Curr Diab Rep"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726068324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726068324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:31:59Z","timestamp":1785853919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726068324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0735109726068324"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.06.012","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy for Management of Type 2 Diabetes and CKM Syndrome","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.03.056","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}